'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points,' wrote the author of a large-scale study on omega-3s published in the New England Journal of Medicine .
'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points,'ÃÂ wrote the author of a large-scale study on omega-3s published in the New England Journal of Medicine .
From April 2002 to December 2006, 4837 patients with a history of heart attacks were enrolled in a 40-month cohort study known as the Alpha Omega Trial Group. One of four margarines'”containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), all three omega-3s, or placebo'”was added to each subject...s daily diet, and individual rates of major cardiovascular incidents were measured.
None of the three omega-3s resulted in a reduction of cardiovascular events compared to placebo. The biggest hint of improvement with omega-3 was identified in women who experienced a reduction with ALA that only 'approached significance.'ÃÂ
Such a long-term and large-scale study might send a bad signal about omega-3s, but hold your thoughts.
Since all of the involved patients had history of cardiovascular problems, the study...s author noted that 'The lack of an effect of EPA-DHA in our trial could be due to an improvement in cardio-protective drug treatment,'ÃÂ as all patients were reported as having been enrolled in prescription drug therapy.
The author went on to state that for cardiovascular patients who are receiving good clinical care and are at a low-risk of heart attacks, 'a beneficial effect of low doses of EPA-DHA is difficult to prove.'ÃÂ
The non-significant improvement in women from ALA may have even been due to change, wrote the lead researcher.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.